Clinical trial
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
NCT00062751 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00062751 |
|---|---|
| Title | Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms |
| Official title | A Phase 2 Randomized Open-Label Study Of Letrozole In Combination With Two Dose Levels And Schedules Of Oral Temsirolimus (CCI-779), Or Letrozole Alone, In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Letrozole / Temsirolimus (CCI-779), Letrozole |
| Enrollment | 108 |
| Start date | Dec 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Oct 1, 2009 |
| First posted | Jun 13, 2003 |
| Last update posted | Apr 15, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: